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Chemotherapy Dose Intensity and Survival in Non-small Cell Lung Cancer
To the Editor: Brunetto et al. 1 noted that modest chemotherapy dose reductions did not have any major impact on survival in patients with non-small cell lung cancer (NSCLC) treated with platinum-doublet chemotherapy and proposed that this might be due to comorbidities, the impact of resistance factors such as excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1) or marked sensitivity to therapy in some of the responders. We had previously converted response rates into hypothetical mean percent tumor cell kill for a large number of published clinical trials in NSCLC and had used nonlinear regression analysis to assess the relationship between hypothetical log mean cell kill and planned dose intensity. 2 For all platinum combinations assessed, dose-response curves flattened at higher chemotherapy doses. Low chemotherapy doses were better than no therapy, but high doses were no better than low doses.
We had previously hypothesized that one could infer resistance mechanisms from the shape of the dose-response curve and that presence of a resistance factor (e.g., the ERCC1 mentioned by Brunetto et al.) would give a shoulder on the dose-response curve when log cell survival was plotted against linear doses (analogous to competitive inhibition of drug effect). 3 Mutation of an obligate target or activating system, would give a reduced slope on the curve, analogous to decreased affinity of a drug for its target. 3 Deficiency or saturation of something required for drug effect (e.g., a drug uptake or activating system, proapoptotic factors, or cells in a sensitive phase of the cell cycle) would give an initial downward slope followed by a terminal plateau (analogous to noncompetitive inhibition of drug effect). 3 On the basis of our hypothesis and on our observation of the flattening of the doseresponse curve in NSCLC, we postulated that our inability to cure metastatic NSCLC with chemotherapy is ultimately due to deficiency or saturation of something required for drug efficacy. Furthermore, as no metastatic epithelial cancer can be cured even by high-dose chemotherapy, we hypothesized that all epithelial cancers (e.g., breast, colorectal, and lung cancers) may share a common reason for this incurability. 2 For different epithelial cancers or for different patients with the same type of cancer, a higher or lower maximum cell kill may be achievable, and it may take fewer or more drugs or higher or lower doses to achieve this maximum cell kill, but the outcome is ultimately the same. Resistance factors such as ERCC1 could affect degree of palliation in individual patients but would not in themselves be responsible for incurability.
A corollary of this is that, even if all epithelial cancers are incurable when metastatic, higher drug doses, or addition of more agents may be useful for relatively sensitive tumors such as breast and small cell lung cancer (SCLC) but would be much less useful for more resistant tumors such as NSCLC and pancreatic cancer. In keeping with this, when we did the same type of analysis in SCLC as in NSCLC, the maximum achievable cell kill was greater in SCLC, and cell kill seemed to keep increasing over a wider dose range, but a maximum possible cell kill was nevertheless ultimately reached. 4 A second corollary is that if we are correct that a common mechanism is responsible for the incurability of all epithelial malignancies, then a single new approach targeting this mechanism could similarly have a dramatic impact on outcome of a broad spectrum of epithelial malignancies. the VEGF expression on immunohistochemistry and short survival of MPM. Yasumitsu et al. reported in their article that patients with MPM demonstrated higher levels of serum VEGF than those of normal subjects. In addition, they also mentioned that patients group of MPM with higher serum levels of VEGF had shorter overall survival than those with lower level; however, in their report, serum VEGF levels showed significant tendencies to increase as the clinical stage went up. Based on these findings, it is supposed that patients with higher serum levels of VEGF contained more patients with advanced stage of MPM. These findings indicate that serum levels of VEGF reflect the tumor burden or disease progression of MPM. In such situation, the prognostic significance should be examined based on multivariate analysis as Cox regression model, as in the report of Demirag et al. At this point, we suppose we had better be more cautious about the prognostic significance of serum VEGF in MPM.
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How Do We Do It?
Another Optimal Methodology for Endobronchial Ultrasound Sample Handling
To the Editor:
We read with great interest the article by Nakajima and Yasufuku 1 in the January issue of the Journal of Thoracic Oncology. These authors reported a methodology for analysis of samples obtained by endobronchial ultrasound (EBUS), not only initially developed for mediastinal staging of non-small cell lung carcinoma (NSCLC) but also widely used for the initial diagnosis of mediastinal metastatic lymph nodes. In this article, they report a multidirectional analysis to obtain precise diagnosis and molecular testing, particularly emphasizing the critical use of freshly stored material.
We would like to report our own experience of a cell aspirate freezing method, allowing multiple cell analyses. This method, although it presents certain similarities with that described by Nakajima and Yasufuku, has a number of notable differences.
Our sampling method has already been described. 2 The entire procedure is performed by a cytopathologist for rapid on-site examination and specimen handling. One to three smears are performed for each aspirate, and in the case of abundant material, the extra aspirate is flushed into a tube containing Roswell Park Memorial Institute cell culture medium. After the last aspirate, the needle is rinsed with culture medium to obtain a cell suspension. Clots or tissue fragments, when observed are removed, fixed in 10% formalin, and paraffin embedded for cell blocks. Representativeness of cell suspensions is checked by a stained cytospin examination. Cell suspensions are centrifuged, and cell pellets are frozen at Ϫ80°C in 20% dimethylsulfoxide (Sigma, France) as usually performed for cell lines: one to four frozen aliquots are stored per specimen. When complementary techniques are required, the samples are thawed, and cytospin is performed to check the quality of the cells. It must be emphasized that this method of cell freezing is usually associated with very well-preserved cell morphology.
Depending on the suspected diagnosis, frozen and fresh cells can be investigated by various methods. Flow cytometry is used for the diagnosis of lymphoma (lymphocyte immunotyping), small cell lung carcinoma (CD56 expression), or DNA ploidy. Tumor cell differentiation markers (TTF1, P63, CK7/CK20, estrogen receptors) are studied in NSCLC or in patients with a history of extrathoracic cancer, either on smears, cytospins from frozen cells or cell blocks. Molecular analysis for EGFR and Ras mutations is performed on thawed cell pellets in NSCLC, and fluorescence in situ hybridization analysis is performed on cytospins from frozen cells.
In conclusion, we agree with Nakajima and Yasufuku that an optimal methodology is essential for the management of specimens obtained by EBUS-TBNA, particularly when rapid on-site examination is not possible. Fresh cell aspirates in cell culture medium stored at Ϫ80°C in dimethylsulfoxide, which is a very simple method, ensure optimal cell preservation for morphology, allowing a wide range of complementary techniques (flow cytometry, molecular genotyping, etc.).
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